CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 33 enrolled
Drug / intervention
4 mg CLS-TA Suprachoriodal Injection +1 moredrug
Likely dose
4 mg CLS-TA Suprachoriodal Injectionfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02952001
NCT02952001N/ACompleted
CompareCT.gov

MAGNOLIA: Multi-Center, Non-Interventional Extension Study of the Safety and Efficacy of CLS-TA for the Treatment of Macular Edema Associated With Non-Infectious Uveitis

Clearside Biomedical, Inc.·observational·Posted Nov 1, 2016·Updated Jun 2, 2021

In Brief

An observational study evaluating 4 mg CLS-TA Suprachoriodal Injection and Sham procedure for Uveitis and 4 related conditions. Completed, enrolled 33 participants across 16 sites in 2 countries.

Detailed Summary

This study is a non-interventional, observational extension of the Parent study, CLS1001-301 (NCT02595398). The purpose of this study is to characterize the continued clinical benefit(s) regarding safety and efficacy of suprachoroidally administered CLS-TA, triamcinolone acetonide injectable suspension, for the treatment of macular edema associated with non-infectious uveitis.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsUveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
CountriesIndia, United States
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedNov 1, 2016
Enrollment StartDec 13, 2017
Primary CompletionMay 22, 2018
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 9.7 years ago

Interventions

4 mg CLS-TA Suprachoriodal Injectiondrug

This drug was administered in the Parent study, CLS1001-301 (NCT02595398). No study treatments were administered during this observational extension study.

Sham proceduredrug

This drug was administered in the Parent study, CLS1001-301 (NCT02595398). No study treatments were administered during this observational extension study.